ISARNA Therapeutics GmbH
- Country
- 🇩🇪Germany
- Ownership
- Holding
- Established
- 1998-01-01
- Employees
- 1
- Market Cap
- -
Phase I Dose Escalation Study to Investigate the Safety of ISTH0036 in Subjects With Glaucoma Undergoing Trabeculectomy
- Conditions
- Primary Open Angle Glaucoma
- Interventions
- Drug: TGF-β2 antisense oligonucleotideProcedure: Trabeculectomy
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- Isarna Therapeutics GmbH
- Target Recruit Count
- 13
- Registration Number
- NCT02406833
- Locations
- 🇩🇪
University Hospital Magdeburg, Ophthalmology, Magdeburg, Germany
🇩🇪Department of Ophthalmology, Johannes-Gutenberg University Mainz, Mainz, Germany
🇩🇪University of Tuebingen, Center of Ophthalmology, Tuebingen, Germany
Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2
- Conditions
- MelanomaColorectal NeoplasmsPancreatic Neoplasms
- Interventions
- First Posted Date
- 2009-02-13
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Isarna Therapeutics GmbH
- Target Recruit Count
- 62
- Registration Number
- NCT00844064
- Locations
- 🇩🇪
Universitätsmedizin Berlin Charité, Berlin, Germany
🇩🇪Universitätsklinik und Poliklinik für Innere Medizin I, Halle (Saale), Germany
🇩🇪Universitätsklinikum Schleswig-Holstein, Kiel, Germany
Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
- Conditions
- Anaplastic AstrocytomaGlioblastoma
- Interventions
- Device: Drug delivery system for administration of AP 12009Procedure: Placement of Drug Delivery System
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2014-11-14
- Lead Sponsor
- Isarna Therapeutics GmbH
- Target Recruit Count
- 27
- Registration Number
- NCT00761280
- Locations
- 🇦🇷
FLENI, Ciudad Autónoma de Buenos Aires, Argentina
🇺🇸NJ Neuroscience Institute; JFK Medical Center, Edison, New Jersey, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
- Conditions
- GlioblastomaAnaplastic Astrocytoma
- Interventions
- Device: Drug delivery system for administration of AP 12009Procedure: Placement of Drug Delivery System
- First Posted Date
- 2007-02-06
- Last Posted Date
- 2013-12-03
- Lead Sponsor
- Isarna Therapeutics GmbH
- Target Recruit Count
- 141
- Registration Number
- NCT00431561
- Locations
- 🇩🇪
Medizinische Klinik und Poliklinik mit Schwerpunkt Onkologie und Hämatologie, Charité Campus Mitte, Berlin, Germany
🇩🇪Klinik und Poliklinik für Neurologie, Cottbus, Germany
🇩🇪Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany